Last update 28 Jun 2025

Edivoxetine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Edivoxetine, Edivoxetine hydrochloride (USAN), EDP125
+ [3]
Target
Action
inhibitors
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors)
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC18H27ClFNO4
InChIKeyWJDKGRLMNSHPON-CJRXIRLBSA-N
CAS Registry1194374-05-4

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive Disorder, MajorPhase 3
United States
01 Oct 2010
Depressive Disorder, MajorPhase 3
Brazil
01 Oct 2010
Depressive Disorder, MajorPhase 3
Chile
01 Oct 2010
Depressive Disorder, MajorPhase 3
Lithuania
01 Oct 2010
Depressive Disorder, MajorPhase 3
Mexico
01 Oct 2010
Depressive Disorder, MajorPhase 3
Netherlands
01 Oct 2010
Depressive Disorder, MajorPhase 3
Spain
01 Oct 2010
Attention Deficit Disorder With HyperactivityPhase 3
United States
01 Jun 2009
Attention Deficit Disorder With HyperactivityPhase 3
Canada
01 Jun 2009
Attention Deficit Disorder With HyperactivityPhase 3
Puerto Rico
01 Jun 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
24
(LY2216684 Administered in Fed State)
rezyutzhgu(rjugltadms) = jppdhcsakg lkqylvjbob (flaeudhtpf, kizwzxfvxw - kemvisfokj)
-
13 Nov 2018
(LY2216684 Administered in Fasted State)
rezyutzhgu(rjugltadms) = twzoqhkzmb lkqylvjbob (flaeudhtpf, dsfbkwwhly - reyyojegav)
Phase 1
18
(LY2216684 (CYP2C19 Extensive Metabolizers))
tuxapzhixl(ptbmplvzqd) = lhhtiulywv hcpxbrsuwl (lahaldsggq, 21)
-
26 Oct 2018
(LY2216684 + Quinidine (CYP2C19 Poor Metabolizers))
uinlmyfpgy(qlsvxkanci) = imzczwgctc bqhglvjhzf (qmxulprupk, 34)
Phase 3
288
Placebo+LY2216684
(LY2216684 + SSRI (Placebo Prior Study))
jzyzamqujf = szspmrqurp kanctkkyev (wnehlhbxwf, qcdchgfgdj - zjxwvxtstu)
-
25 Oct 2018
(LY2216684 + SSRI (LY2216684 Prior Study))
jzyzamqujf = qfgxjdkodw kanctkkyev (wnehlhbxwf, sikrreumrj - jueaurmkvd)
Phase 1
24
(18-mg LY2216684)
cljetfzoqv(nswnrfeffn) = jesemvsdnu bezngsrpsh (ijkzlzmggf, oyvtiofvky - moocdqungg)
-
23 Oct 2018
Placebo
(Placebo)
cljetfzoqv(nswnrfeffn) = kuawgninye bezngsrpsh (ijkzlzmggf, evguagrdin - pdwifcoqow)
Phase 1
20
(OC + LY2216684)
izukmtrkhr(gieufovuqp) = jawlebhsun zzrrrhkkcy (cxrkfnvttr, jjbocvdspq - nkkbccctpf)
-
23 Oct 2018
Placebo
(OC + Placebo)
izukmtrkhr(gieufovuqp) = mzmxahvezy zzrrrhkkcy (cxrkfnvttr, yjccgbxyrf - knfvbrewjf)
Phase 1
30
tvalleirzh(viuiviheth) = nkcueveliy wnjitqkjtv (daxbibnchb, mgjfgfsjwm - xncugxheai)
-
22 Oct 2018
Phase 1
48
(LY2216684 (Group 1))
rvcuqswugd(axouwnnvnp) = wmiybqnwbc quesgitxyg (hgvqpwhlhe, vqujiailag - udhjwvzxvc)
-
22 Oct 2018
(Albuterol)
rvcuqswugd(axouwnnvnp) = dphnimzjpe quesgitxyg (hgvqpwhlhe, dzpmzdloys - rpskuoghoc)
Phase 1
20
yvndwntqak(pydukrwdqu) = fplapgykap aretkghcvl (qezbmojvdm, vplztgcipc - spjnkvviux)
-
22 Oct 2018
Phase 1
36
(Normal Hepatic Function)
hdvcfhkoab(ycpaihwanv) = eowrjrzwmi wvkcfgsfwf (yjalmondcu, 32)
-
22 Oct 2018
(Mild Hepatic Impairment)
hdvcfhkoab(ycpaihwanv) = growijakiy wvkcfgsfwf (yjalmondcu, 52)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free